started · updated
Novo Nordisk unveils 2030 growth strategy amid patent concerns
Novo Nordisk faces investor skepticism following its Capital Markets Day in London, where the company unveiled a long-term growth strategy aimed at offsetting the upcoming patent expiration of semaglutide. The drug, used in Wegovy and Ozempic, is expected to lose patent protection in the US and Europe in the early 2030s.
To counter this, CEO Mike Doustdar announced plans to launch more than five multi-blockbuster drugs by 2030 and target over DKK 150 billion in risk-adjusted pipeline sales by 2035. The company is also focusing on expanding its oral GLP-1 capacity and diversifying into other therapeutic areas. Clinical data for the next-generation combination therapy, CagriSema, showed significant weight loss results in Phase 3 trials, including a 21% reduction in the REDEFINE 9 study.
Despite these ambitions, Novo Nordisk shares fell as much as 9% as analysts expressed concerns regarding pricing power, margin stability, and the company's ability to compete with rivals like Eli Lilly. Additionally, the company confirmed that restructuring efforts have resulted in a total workforce reduction of 13,000 employees from its peak.
Entities
BMO Capital Markets · CagriSema · Eli Lilly · Maziar Doustdar · Mike Doustdar · Morgan Stanley · Novo Nordisk · Zepbound
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Semaglutide is projected to represent 59% of total sales when its patent expires in Europe in 2031 and the US in 2032. www.foreignpolicyjournal.com
- [○ 1 SOURCE] Novo Nordisk plans to launch more than five drugs with multiple billions of dollars in annual sales through 2030. www.genengnews.com
- [○ 1 SOURCE] LSEG projects Zepbound sales will exceed Wegovy sales by more than $7 billion in 2026. blockonomi.com
- [○ 1 SOURCE] Morgan Stanley downgraded Novo Nordisk to Underweight. www.foreignpolicyjournal.com
- [○ 1 SOURCE] BMO Capital Markets suggests Novo's 2026-2030 revenue growth targets may be underwhelming compared to industry peers. www.genengnews.com
- [● 5 SOURCES] The company aims to generate more than DKK 150 billion in risk-adjusted pipeline sales by 2035. www.genengnews.com · www.spacemoney.com.br · www.hrkatha.com · medicaldialogues.in · www.finanzen.at
- [○ 1 SOURCE] CEO Mike Doustdar identified the upcoming semaglutide patent cliff as a significant risk for the company.
- [● 3 SOURCES] Novo Nordisk has reduced its global workforce by 13,000 employees from its peak. www.hrkatha.com · medicaldialogues.in · www.finanzen.at
- [● 5 SOURCES] Novo Nordisk plans to launch more than five multi-blockbuster drugs with annual sales exceeding billions of dollars through 2030. www.spacemoney.com.br · www.genengnews.com · medicaldialogues.in · finance.technews.tw · www.finanzen.at
- [○ 1 SOURCE] Restructuring measures at the company have led to 13,000 job losses. www.finanzen.at
- [● 6 SOURCES] The patent for semaglutide is expected to expire in the US in 2032. www.stiripesurse.ro · finance.technews.tw · www.foreignpolicyjournal.com · blockonomi.com · www.finanzen.at · +1 more
- [● 5 SOURCES] Novo Nordisk aims to launch at least five multi-blockbuster drugs by 2030. finance.technews.tw · www.boersennews.de · www.finanzen.at · www.stiripesurse.ro · www.expansion.com